In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how pharmaceutical companies can effectively balance personalized marketing efforts with maintaining data privacy and ensuring patient trust.

S-HiCon can reportedly achieve stable liquid formulation for over 200 mg/mL subcutaneous administration.

MedHub has been expanded to work with a wider variety of insurance plans.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.

Acquisition of Longboard grants Lundbeck access to bexicaserin, 5-HT2C receptor agonist that has demonstrated promise in treating seizures associated with rare developmental epileptic encephalopathies.

Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors.

Practical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.

The latest news for pharma industry insiders.

Roaldi previously served as chief growth officer for UnitedHealthcare Community & State.

The challenges in obesity research are significant, but the opportunities for innovation are equally profound.

Respondents showed concern for cost increases and changes to benefits.

JAMA study finds that redispensing oral anticancer drugs reduces approximately two-thirds of medication waste as healthcare stakeholders seek more sustainable practices.

The campaign comes during a time when the nation is facing a blood shortage.

Three key components to scaling quickly—while maintaining purpose.

Approval was based on results from the Phase III INAVO120 trial, which found that Itovebi in combination with palbociclib and fulvestrant significantly improved progression-free survival in patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

Announcements such as Apple’s come with pros and cons for industry.

A value deficit and potential consumer value proposition.

Laura Johnson, senior director, sales, life sciences, Loftware, discusses integrating digital solutions with traceability and drug administration.

The two companies will continue to collaborate on weight loss medications.

The latest news for pharma industry insiders.

The program will now cover 15 gene and cell therapies.

Data from the Phase III AReSVi-006 clinical trial found that Arexvy offered a cumulative efficacy of 62.9% against lower respiratory tract disease caused by respiratory syncytial virus.

Healgen’s Rapid Check COVID-19/Flu A&B Antigen Test is the first non-prescription COVID-19/flu combination test to be authorized by the FDA without emergency use authorization.

A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.